GLP-1’s is well known for helping with type 2 diabetes and weight management, but researchers are now studying its effects on brain health. Early studies suggest that GLP-1 medications may reduce the risk of Alzheimer’s disease and dementia by supporting vascular function, reducing inflammation, and improving insulin sensitivity. Although, GLP-1’s are not approved for cognitive conditions, it is being closely researched as a therapy for protecting memory and cognitive function.
About Alzheimer’s and Dementia
Alzheimer’s disease is the most common form of dementia, affecting many individuals worldwide. Dementia involves a decline in memory, reasoning, and other cognitive abilities affecting daily life. Treatment options remain limited for those who have developed dementia or Alzheimer’s, and many therapies only address symptoms rather than slowing or preventing disease progression.
About GLP-1’s
GLP-1’s (glucagon-like peptide-1) receptor agonist originally developed to manage type 2 diabetes. It works by improving insulin sensitivity, reducing blood sugar, and suppressing appetite, making it effective for both blood sugar control and weight loss.
How GLP-1’s May Lower Risk of Alzheimer’s or Dementia
Research has shown that patients taking GLP-1 medications may have a lower risk of cognitive decline compared to those on other therapies. Scientists believe this connection may be due to the drug’s ability to reduce inflammation, improve vascular health, and support brain cell signaling while also addressing insulin resistance, which is strongly linked to memory loss. Evidence from clinical trials has suggested potential benefits for alzheimers patients, with some results indicating a lower incidence of dementia in those treated with GLP-1 medications. A new study has further explored how these drugs could help reduce risk factors tied to obesity, one of the leading contributors to brain aging and vascular disease.
In addition to controlled research, there is also real world evidence showing similar outcomes among older adults who use these medications. The potential impact may extend beyond Alzheimer’s disease to conditions such as vascular dementia, which is often influenced by circulation problems and metabolic health. With more data linked to long-term use, researchers are optimistic that these findings will shape future approaches to preventing neurodegenerative conditions.
GLP-1 Treatment
Currently, GLP-1’s is created for diabetes and weight management, not for the treatment of Alzheimer’s or dementia. However, ongoing studies may expand its use into cognitive medicine. Patients can benefit from its aid in metabolic health, while researchers continue to evaluate its impact on protecting memory and brain function.
Schedule a Consultation
At Modern Surgical Arts of Denver, Dr. Kamran Dastoury and the team stay at the forefront of medical innovation to keep patients informed about new possibilities for health and wellness. To learn more about GLP-1 therapies, and whether these treatments may be right for you, contact our Denver office today by completing the online contact form to schedule a consultation.
Dr. Kamran Dastoury
Dr. Kamran Dastoury is a double board-certified cosmetic surgeon with advanced training in both maxillofacial and aesthetic surgery, bringing unmatched expertise to every patient he serves. After earning his dental and medical degrees from USC and LSU, he went on to complete over seven years of intensive surgical training, including a fellowship in facial and body cosmetic surgery under the mentorship of world-renowned leaders in the field. His specialties include facelifts, rhinoplasty, eyelid surgery, liposuction, and body contouring—always delivered with a highly personalized approach that prioritizes safety, artistry, and natural-looking results. Beyond his surgical excellence, Dr. Dastoury is deeply committed to advancing the field through research, teaching, and global mission work, making him a trusted and compassionate choice for patients seeking transformative results.